Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Advaxis Shares Surge After Positive Clinical Trial Updates

Benzinga.com  April 1, 2019

AstraZeneca's Rare Pediatric Genetic Disorder Drug Granted Breakthrough Therapy Designation

Benzinga.com  April 1, 2019

Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019

Business Wire April 1, 2019

Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy

Business Wire April 1, 2019

Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1

Business Wire April 1, 2019

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Benzinga.com  March 29, 2019

BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting

GlobeNewswire March 26, 2019

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion

PR Newswire March 25, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Benzinga.com  March 23, 2019

The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback

Benzinga.com  March 22, 2019

BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering

GlobeNewswire March 20, 2019

Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development

Business Wire March 20, 2019

Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022

Business Wire March 20, 2019

IMMUNE DESIGN CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger

GlobeNewswire March 18, 2019

New Treatment Option Now Available in Canada for Newly Diagnosed Patients with Advanced Lung Cancer

Canada NewsWire March 18, 2019

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Business Wire March 14, 2019

BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire

GlobeNewswire March 7, 2019

Merck Prices $5.0 Billion Debt Offering

Business Wire March 5, 2019

Merck Begins Tender Offer to Acquire Immune Design

Business Wire March 5, 2019

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications

Business Wire March 4, 2019